Phase 2 randomized study of enzastaurin (LY317615) for lung cancer prevention in former smokers

Cancer

Volumn 119, Issue 5, 2013, Pages 1023-1032

  Gray, Jhanelle E ^a   Altiok, Soner ^a   Alexandrow, Mark G ^a   Walsh, Frank W ^a   Chen, Jian ^b   Schell, Michael J ^a   Tai, Datchen Fritz ^b   Bepler, Gerold ^a,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c KARMANOS CANCER INSTITUTE   (United States)

Author keywords

apoptosis; biomarkers.; caspase 3; chemoprevention; enzastaurin; glycogen synthase kinase 3 ; Ki 67; lung cancer; nonsmall cell lung cancer; protein kinase C

Indexed keywords

ENZASTAURIN; KI 67 ANTIGEN; PLACEBO; PROTEIN KINASE C BETA;

ABDOMINAL DISTENSION; ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BRADYCARDIA; BRONCHUS BIOPSY; CANCER STAGING; CELL FRACTIONATION; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; HYPOTENSION; INTENTION TO TREAT ANALYSIS; LABELING INDEX; LUNG CANCER; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOKING; URINE COLOR;

AGED; FEMALE; HUMANS; INDOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PRECANCEROUS CONDITIONS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; RISK; SMOKING;

EID: 84874245854     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27836     Document Type: Article

References (32)

1. World Health Organization (WHO). World Health Organization 2011 Cancer Fact Sheet. No. 297, February 2011. Geneva, Switzerland: WHO; 2011. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed September 26, 2011.
2. Sendowski M, Bepler G,. Chemoprevention for lung cancer. Oncol Spectrums. 2002; 3: 116-126.
3. Hong WK, Sporn MB,. Recent advances in chemoprevention of cancer. Science. 1997; 278: 1073-1077.
4. Khuri FR, Lippman SM,. Lung cancer chemoprevention. Semin Surg Oncol. 2000; 18: 100-105.
5. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994; 330: 1029-1035.
6. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996; 334: 1145-1149.
7. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996; 334: 1150-1155.
8. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H,. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J Natl Cancer Inst. 2000; 92: 977-986.
9. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst. 2001; 93: 605-618.
10. Keith RL, Blatchford PJ, Kittelson J, et al. Oral iloprost improves endobronchial dysplasia in former smokers. Cancer Prev Res. 2011; 4: 793-802.
11. Shiba M, Kohno H, Kakizawa K, et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected non-small cell lung carcinoma. Cancer. 2000; 89: 1457-1465.
12. Ramnath N, Hernandez FJ, Tan DF, et al. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer. J Clin Oncol. 2001; 19: 4259-4266.
13. Gescher A,. Analogs of staurosporine: potential anticancer drugs? Gen Pharmacol. 1998; 31: 721-728.
14. Jarvis WD, Grant S,. Protein kinase C targeting in antineoplastic treatment strategies. Invest New Drugs. 1999; 17: 227-240.
15. Parker PJ,. Inhibition of protein kinase C-do we, can we, and should we? Pharmacol Ther. 1999; 82: 263-267.
16. Castagna M, Takai Y, Kaibuchi K, et al. Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982; 257: 7847-7851.
17. Kikkawa U, Takai Y, Tanaka Y, et al. Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem. 1983; 258: 11442-11445.
18. Leach KL, James ML, Blumberg PM,. Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. Proc Natl Acad Sci U S A. 1983; 80: 4208-4212.
19. Murray NR, Davidson LA, Chapkin RS, Clay Gustafson W, Schattenberg DG, Fields AP,. Overexpression of protein kinase C beta-II induces colonic hyperproliferation and increased sensitivity to colon carcinogenesis. J Cell Biol. 1999; 145: 699-711.
20. Chida K, Hara T, Hirai T, et al. Disruption of protein kinase C-eta results in impairment of wound healing and enhancement of tumor formation in mouse skin carcinogenesis. Cancer Res. 2003; 63: 2404-2408.
21. Griner EM, Kazanietz MG,. Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007; 7: 281-294.
22. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase C beta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res. 2005; 65: 7462-7469.
23. Tan DF, Huberman JA, Hyland A, et al. MCM2-a promising marker for premalignant lesions of the lung: a cohort study [serial online]. BMC Cancer. 2001; 1: 6.
24. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G,. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007; 356: 800-808.
25. Oh Y, Herbst RS, Burris H, et al. Evaluation of enzastaurin, an oral, serine/threonine kinase inhibitor, as second- or third-line therapy of non-small cell lung cancer. J Clin Oncol. 2008; 26: 1135-1141.
26. Camp RL, Chung GG, Rimm DL,. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002; 8: 1323-1327.
27. Korner A, Mudduluru G, Manegold C, et al. Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules. Br J Cancer. 2010; 103: 802-811.
28. Chiappori A, Bepler G, Barlesi F, et al. Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 369-375.
29. Mao JT, Roth MD, Fishbein MC, et al. Lung cancer chemoprevention with celecoxib in former smokers. Cancer Prev Res (Phila). 2011; 4: 984-993.
30. Kim ES, Hong WK, Lee JJ, et al. Biological activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res (Phila). 2010; 3: 148-159.
31. Szabo E,. Assessing efficacy in early phase cancer prevention clinical trials: the case of Ki-67 in the lung. Cancer Prev Res. 2010; 3: 128-131.
32. Szabo E,. Altered histology provides a positive clinical signal in the bronchial epithelium. Cancer Prev Res. 2011; 4: 775-778.